Cargando…
Liver fibrosis and adverse outcomes in COVID-19
Autor principal: | Huang, Jianmin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015429/ https://www.ncbi.nlm.nih.gov/pubmed/33994131 http://dx.doi.org/10.1016/j.dld.2021.03.024 |
Ejemplares similares
-
Reply to: “Liver fibrosis and adverse outcomes in COVID-19”
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021) -
The Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With COVID-19
por: Dai, Cong, et al.
Publicado: (2021) -
Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
por: Kow, Chia Siang, et al.
Publicado: (2020) -
Diethylcarbamazine as potential treatment of COVID-19 lung fibrosis
por: Medina-De la Garza, Carlos Eduardo, et al.
Publicado: (2022) -
Impact of Preexisting Chronic Liver Disease on the Outcome of Patients With COVID-19 Disease
por: Verma, Nipun, et al.
Publicado: (2021)